Stephanie Dunlap – Review of Guidelines Directed Medical Therapy of CHF
Salepage link: At HERE. Archive:
- State Associations:
- GOMA – Georgia
- Faculty:
- Stephanie Dunlap, DO
- Duration:
- 55 Minutes
- Expiration:
- Never expires.
Description
Learning Objectives:
1. Name meds used for systolic heart failure
2. Describe the advantages of the newest med for heart failure
3. Define Systolic Heart failure
The Georgia Osteopathic Medical Association is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians and designates this program for a maximum of 1.0 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity.
Grievance Policy:
All grievances should be in writing and should specify the nature of the grievance. Initially, all grievances should be directed to GOMA’s Executive Director, who will then forward said grievance to the CME Planning Committee. All grievances will receive an initial response in writing within 30 days of receipt. If the participant does not receive a satisfactory response, then they can then submit a complaint in writing to the Bureau of Osteopathic Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.
Faculty
Stephanie Dunlap, DO Related seminars and products: 1
Stephanie Dunlap, DO, Professor of Medicine, Medical Director, Advanced Heart Failure and Coronary Care Unit, Augusta University
Dr. Dunlap, a native of West Virginia attended West VWSOM. She did her internship and residency in Southern Florida, then traveled to NC where she completed her Cardiovascular Fellowship and two years of clinical heart failure research. She then completed a fellowship in heart transplantation and MC5 at the Cleveland Clinic. Since then, she has had academic appointments at Rush University, University of Illinois at Chicago, University of Cincinnati, and is now at Medical College of Georgia, Augusta University where she is Director of Advance Heart Failure and where she expects to launch an MC5/LVAD program July, 2021.
DISCLOSURE: Grants: Bayer Healthcare and NIH
